Full Data For Seattle Genetics' Lymphoma Drug Shine Bright Light On Antibody Drug Conjugates

Pivotal trial data look good for soon-to-be-filed orphan lymphoma candidate, partnered with Takeda. SGN-35 may be among the first conjugates to hit the U.S. market, with launch projected for third quarter 2011.